{"member_organisations": "http://www.eucope.org/en", "identification_number": "838328429683-62", "fields_of_interest": "General and Institutional Affairs, Economy, finance and the euro, Trade, Competition, Consumers, Employment and Social Affairs, Business and Industry, Taxation, Single market, Research and innovation, Public Health", "head_office_address": "Dammstrasse 19", "full_time_equivalent_fte": "0,25", "person_with_legal_responsibility": "Theresa Heggie", "industry_forums": "", "grants": "", "country_code": "ch", "inter_groups": "", "eu_initiatives": "Alnylam is committed to making the therapies we develop available to those who will benefit from them. We seek to be involved in policy developments that improve regulatory processes for pharmaceuticals and ensure the right environment for research, \ninnovation and industry in Europe. We aim at participating in debates around improved and equal access to innovative medicines for \npatients through open dialogues with European policy-makers.", "level_of_interest": "global", "organisation_name": "ALNYLAM PHARMACEUTICALS (ALNY)", "belgium_office_post_code": "", "number_of_persons_involved": "1", "person_in_charge_of_eu_relations": "Julien Patris", "section": "II - In-house lobbyists and trade/business/professional associations", "lon": "8.51439045", "source": "", "subsection": "Companies & groups", "belgium_office_phone": "", "overall_budget_turnover_as_a_range": "", "belgium_office_address": "", "persons_accredited_for_access_to_european_parliament_premises": "", "registration_date": "18/01/2018", "estimate_of_costs_absolute_amount": "", "website_address": "http://www.alnylam.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Zug", "membership": "Alnylam is Member of European Confederation of Pharmaceutical Entrepreneurs (EUCOPE, http://www.eucope.org/en)", "head_office_post_code": "6300", "position": "Associate Director Market access & Policy Europe & Canada", "financial_year_start_date": "01/01/2017", "head_office_country": "Switzerland", "number_of_ep_accredited_persons": "", "relevant_communication": "", "financial_year_end_date": "01/12/2017", "lat": "47.17635225", "estimate_of_costs_as_a_range": "25000-49999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Corporation, publicly traded", "procurement": "", "customers": "", "belgium_office_post_box": "", "goals__remit": "Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to \ntransform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi \ntherapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high \nunmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by \nits robust discovery platform and deep pipeline of investigational medicines.", "belgium_office_city": "", "head_office_phone": "(+41)41 561 3500"}